Immunotherapy最新文献_第3页

Germinal center immune dynamics: challenges for effective vaccination in the elderly. 生发中心免疫动力学：老年人有效疫苗接种的挑战。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-14 DOI: 10.1080/1750743X.2025.2546279

Cloe Brenna, Constantinos Petrovas

{"title":"Germinal center immune dynamics: challenges for effective vaccination in the elderly.","authors":"Cloe Brenna, Constantinos Petrovas","doi":"10.1080/1750743X.2025.2546279","DOIUrl":"10.1080/1750743X.2025.2546279","url":null,"abstract":"Follicular (F) and germinal center (GC) immune dynamics are crucial in generating pathogen-specific antibodies with high affinity and neutralizing activity capable of combating infections. GCs are populated by highly differentiated CD4 T-cell and B-cell populations with unique phenotypes, functions, and molecular signatures. Aging, which is associated with a state of \"immunosenescence,\" is characterized by compromised B-cell responses to infections and reduced vaccine efficacy, pointing to altered GC immunoreactivity and function. Therefore, there is a need for novel, improved approaches to strengthen antibody responses in these individuals and mitigate morbidity and mortality. Despite the importance of mouse models, studies focusing on human F/GC immune dynamics are of great interest. Furthermore, studying these dynamics in various human diseases could provide important insights into the cellular and molecular mechanisms that regulate GC development under different local microenvironmental conditions. The development and application of cutting-edge methodologies allowing for the comprehensive analysis of relevant cell types and a better understanding of the spatial organization of the immune system in these anatomical sites are essential to delineate the impact of molecular targets and pathways that could be used in designing in vivo immune interventions aiming to strengthen B-cell responses, especially in aging.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"811-822"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144845781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Scalable and cost-effective CAR-T exosome therapies: challenges and future directions. 可扩展和具有成本效益的CAR-T外泌体疗法：挑战和未来方向。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-01 DOI: 10.1080/1750743X.2025.2552105

Xuan Zhao, Huixian Li, Xinwei Zhao, Gaofeng Liang

引用次数: 0

The role of exosomal PD-L1 in NSCLC immunotherapy. 外泌体PD-L1在非小细胞肺癌免疫治疗中的作用

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-30 DOI: 10.1080/1750743X.2025.2539060

Zhu Li, Shichang Zhang, Yue Wang, Yubo Yan

{"title":"The role of exosomal PD-L1 in NSCLC immunotherapy.","authors":"Zhu Li, Shichang Zhang, Yue Wang, Yubo Yan","doi":"10.1080/1750743X.2025.2539060","DOIUrl":"10.1080/1750743X.2025.2539060","url":null,"abstract":"Therapeutic resistance and immune evasion are hallmark features associated with tumor progression, wherein tumor cells utilize programmed death-ligand 1 (PD-L1) to inhibit cytotoxic T-cell activity via programmed cell death protein 1 (PD-1) engagement. Anti-PD-1 monoclonal antibodies have shown tremendous success in multiple cancers. Despite their limited efficacy in non-small cell lung cancer (NSCLC), a deeper investigation into the mechanism of PD-L1-mediated immune evasion is needed to combat therapeutic resistance. While some clinical benefits for anti-PD-L1 therapy have been observed in NSCLC, factors, such as durability of response and resistance mechanisms remain barriers to its broader use. Recent findings suggest that exosomal PD-L1 may serve as a critical mediator in these resistance mechanisms while simultaneously promoting cancer progression. Therapeutically targeting the process of exosome biogenesis, which is controlled by neutral sphingomyelinase 2 (nSMase2) and the Rab proteins, could yield a novel treatment strategy. Evidence suggests that knocking down these regulatory proteins may enhance cancer therapy, but that remains to be seen in NSCLC. This review presents a comprehensive overview of exosomal PD-L1 in lung cancer, considering its implications in therapeutic resistance and novel treatment strategies, positioning it as a valuable resource for advancing next-generation immunotherapy approaches.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"715-725"},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review. 结直肠癌患者免疫检查点抑制的预测性生物标志物：综合综述

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-12 DOI: 10.1080/1750743X.2025.2530853

Ibrahim Halil Sahin, Turcin Saridogan, Richard Kim

{"title":"Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review.","authors":"Ibrahim Halil Sahin, Turcin Saridogan, Richard Kim","doi":"10.1080/1750743X.2025.2530853","DOIUrl":"10.1080/1750743X.2025.2530853","url":null,"abstract":"Immune checkpoint inhibitors have resulted in treatment paradigm changes for the management of patients with solid tumors, including microsatellite instability-high (MSI-H) colorectal cancer (CRC). Although the benefit of these agents appears to be limited for microsatellite stable (MSS) CRC, recent studies suggest that the immune microenvironment of the early-stage MSS CRC and perhaps those with advanced-stage disease without active liver metastasis may be more immune permissive where relatively more promising responses were noted. At this time, biomarkers of immunotherapy for patients with CRC have not been well-defined. Except for the loss of mismatch repair protein (MMR) function and POLE/POLD1 mutations, most of the biomarkers of response are largely investigational. In this review article, we summarize recent research and drug development with immune checkpoint inhibitors for patients with MSS and MSI-H CRC and elaborate on investigational biomarkers, including but not limited to tumor mutation burden and immunoscore. We also discuss the relevance and potential applicability of these biomarkers to clinical practice for the use of immune checkpoint inhibitors and provided further perspective on future biomarker development.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"727-734"},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report. 新辅助免疫治疗孤立性腹膜间皮瘤累及腹壁：一例报告。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-21 DOI: 10.1080/1750743X.2025.2535941

Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano

引用次数: 0

Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection. 用T淋巴细胞和B淋巴细胞耗竭治疗免疫检查点抑制剂相关的移植排斥反应。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-06 DOI: 10.1080/1750743X.2025.2529152

Siqi Qiu, Zhipeng Zong, Kang He

引用次数: 0

Nivolumab induced discolouration of the tongue: a case report. 纳武单抗引起的舌头变色：1例报告。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-13 DOI: 10.1080/1750743X.2025.2533105

Elif Değirmenci Aktaş, Dilek Yildirim

引用次数: 0

Immune checkpoint inhibitors and venous thromboembolism in patients with head and neck cancer undergoing surgery. 头颈癌手术患者的免疫检查点抑制剂和静脉血栓栓塞。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-22 DOI: 10.1080/1750743X.2025.2536460

Kiranya E Arnold, Febronia M Mansour, Komal Akhtar

{"title":"Immune checkpoint inhibitors and venous thromboembolism in patients with head and neck cancer undergoing surgery.","authors":"Kiranya E Arnold, Febronia M Mansour, Komal Akhtar","doi":"10.1080/1750743X.2025.2536460","DOIUrl":"10.1080/1750743X.2025.2536460","url":null,"abstract":"Objective: Venous thromboembolism (VTE) is associated with significant morbidity. Although this risk is multifactorial, recent studies suggest immune checkpoint inhibitors (ICIs) may also contribute to increased VTE risk. The aim of this study is to evaluate VTE risk in a cohort of patients with head and neck cancer treated with surgery and ICIs.Methods: De-identified data from the TriNetX Global Collaborative Network database was used to identify adult surgical patients (≥18 years) using International Classification of Diseases 10th Revision and Common Procedural Terminology codes and were further refined by use of nivolumab, pembrolizumab, or cemiplimab within 1-year before or up to 3-months after surgery. Cohorts were propensity score matched, and the primary study outcome was the 3-month composite rate of VTE.Results: After propensity score matching, there were 1,471 patients in each cohort and they were well balanced according to demographics, body mass index, comorbidities, medication use, and radiation history up to 1-year before the index event. The composite rate of VTE in the study population was 3.7% and was higher in patients treated with ICIs (4.6% versus 2.9%; OR, 1.6; 95% CI, 1.1, 2.5).Conclusions: This study highlights the importance of risk stratification and risk reduction in the setting of increasing ICI use for patients with HNC undergoing surgery.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"709-713"},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatment. CAR-T治疗实体瘤的陷阱和策略以及脊索瘤治疗的意义。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-08-09 DOI: 10.1080/1750743X.2025.2536458

M Qi, G Cattaneo, C Camillo, E Quattrocchi, L Zhang, E Tejeda-Polanco, C Ferrone, Z Chen, J Schwab

{"title":"Pitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatment.","authors":"M Qi, G Cattaneo, C Camillo, E Quattrocchi, L Zhang, E Tejeda-Polanco, C Ferrone, Z Chen, J Schwab","doi":"10.1080/1750743X.2025.2536458","DOIUrl":"10.1080/1750743X.2025.2536458","url":null,"abstract":"In recent years, CAR-T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating remarkable therapeutic efficacy in hematologic malignancies such as leukemia and lymphoma. However, its effectiveness in treating solid tumors remains limited, with challenges such as low response rates, poor therapeutic persistence, and high recurrence rates. The unique and complex immune microenvironment of solid tumors, characterized by a dense extracellular matrix, an abundance of immunosuppressive cells, and cytokines, is considered a major factor impeding CAR-T cell infiltration, antitumor activity, and persistence, significantly hindering the clinical potential of this therapy. To address these challenges, various strategies have been developed to optimize CAR-T cell functionality and adaptability. As a rare and highly complex solid tumor, chordoma presents with several challenges for CAR-T cell therapy, including the lack of tumor-specific antigens, rich extracellular matrix, and enrichment of immunosuppressive factors such as TGF-β. This review summarizes the key challenges and corresponding strategies to enhance CAR-T cell therapy in solid tumors, with a particular focus on underlying its therapeutic potential for the treatment of chordoma.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"735-747"},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. 胰腺癌立体定向放射治疗加过继性vNKT细胞治疗：II期试验方案。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-07-16 DOI: 10.1080/1750743X.2025.2533112

Xiaofei Zhu, Xiaolan Yin, Wenyu Liu, Chunshan Yu, Sheng Xia, Yangsen Cao, Lingong Jiang, Zhenhong Guo, Minghui Zhang, Huojun Zhang

{"title":"Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial.","authors":"Xiaofei Zhu, Xiaolan Yin, Wenyu Liu, Chunshan Yu, Sheng Xia, Yangsen Cao, Lingong Jiang, Zhenhong Guo, Minghui Zhang, Huojun Zhang","doi":"10.1080/1750743X.2025.2533112","DOIUrl":"10.1080/1750743X.2025.2533112","url":null,"abstract":"Aims: Novel and multimodal immunotherapy approaches are required for pancreatic cancer. A novel subset of NKT cells, called CD8+ NKT-like cells or variant NKT (vNKT) cells, which are CD8+ CD56+, CD1d-independent with variant TCR, have been reported to provide potent anti-tumor immunity. With positive immune regulations of stereotactic body radiation therapy (SBRT) reported in previous studies, we hypothesize that there might be a synergy of SBRT with immunotherapy. The aim of this study is to evaluate the efficacy and safety of SBRT plus vNKT cells as adoptive cell therapy for advanced pancreatic cancer.Methods: The prescription dose of SBRT ranges from 35 to 40 Gy/5f. Transfer of allogeneic vNKT cells is initiated 1-2 weeks after SBRT. Patients receive transfusion of vNKT cells twice a month with a 12-24 h interval within 6 months after SBRT and once a month thereafter. A 12-month transfer is defined as a cycle. The primary outcome is overall survival. The secondary outcomes are progression-free survival, adverse events, and quality of life.Conclusion: Therapeutic potential of SBRT plus vNKT cells may provide a novel insight into the treatment for advanced pancreatic cancer, and further investigations on the clinical benefits compared to standard chemoradiotherapy are warranted.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05783076.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"685-692"},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0